Treosulfan for nijmegen breakage syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Nov 2023: Trial started, NCT06198842
  2. 10 Jan 2024: Trial registered, NCT06198842

The trials

NCT06198842: Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome

State
Under way
Phase
Phase 2
People
10 planned
Started
22 Nov 2023
Primary completion
31 Jan 2027
Arms
intervention/treatment
Results
None posted
  1. 22 Nov 2023: Trial started
  2. 10 Jan 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Graftrevo, Kepcondi, Ovastat, Trecondi, Trecondyv, Treograft.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.